Insulin resistance in patients with psoriasis
Main Article Content
Psoriasis is a chronic systemic inflammatory disease accompanied by an activation of skin dendritic cells with accumulation in the inflammatory foci of interleukin-23 and activated Th-1 lymphocytes (Th-17, Th-22). In recent years, there has been a large number of evidence linking psoriasis with other inflammatory diseases, including obesity, diabetes mellitus, atherosclerosis, hypertension, nonalcoholic fatty liver disease, polycystic ovary syndrome, benign prostatic hyperplasia, etc. All of these conditions are associated with systemic inflammation and insulin resistance induced by it. Psoriasis is the most common chronic dermatosis and affects 1–2 % of the population in developed countries. Psoriasis as a chronic immune-mediated inflammatory skin disease is often associated with metabolic syndrome and its components such as obesity, hypertension, insulin resistance and dyslipidemia. The risk of developing metabolic syndrome in patients with psoriasis is 40 % higher than in the general population. Psoriasis and metabolic syndrome share some pathogenic mechanisms such as chronic low-grade systemic inflammation and an increased level of pro-inflammatory cytokines. Systemic inflammation causes obesity, cardiovascular diseases, diabetes mellitus type 2. These conditions increase the risk of mortality among patients with psoriasis. There is a positive correlation between the severity of psoriasis and metabolic syndrome, which is manifested by a severe rash, reduction of the remission and higher risk of psoriatic arthritis development. The carriers of the risk allele of FTO gene are characterized by a more severe psoriasis, the presence of psoriatic arthritis and increased body mass index. A review of the literature focuses on the relationship between insulin resistance and the pathogenesis of psoriasis.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Łebkowska A, Krentowska A, Adamska A, et al. Type B insulin resistance syndrome associated with connective tissue disease and psoriasis. Endocrinol Diabetes Metab Case Rep. 2020 Aug 4;2020:20-0027. doi: 10.1530/EDM-20-0027.
Wen S, Liu C, Li Y, Pan J, Nguyen T, Zhou L. Psoriasis Exacerbates the State of Insulin Resistance in Patients with Type 2 Diabetes. Diabetes Metab Syndr Obes. 2021 May 26;14:2389-2397. doi: 10.2147/DMSO.S312420.
Bajaj S, Mandal S, Singh KG, Prajapati R. Metabolic Diseases and Associated Complications in Patients with Psoriasis. J Assoc Physicians India. 2020 Oct;68(10):44-46.
Polic MV, Miskulin M, Smolic M, et al. Psoriasis Severity – A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome. Int J Environ Res Public Health. 2018;15(7):1486. doi: 10.3390/ijerph15071486.
Abramczyk R, Queller JN, Rachfal AW, Schwartz SS. Diabetes and Psoriasis: Different Sides of the Same Prism. Diabetes Metab Syndr Obes. 2020 Oct 7;13:3571-3577. doi: 10.2147/DMSO.S273147.
Hao Y, Zhu YJ, Zou S, et al. Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions. Front Immunol. 2021;12:711060. doi: 10.3389/fimmu.2021.711060.
Chan WMM, Yew YW, Theng TSC, Liew CF, Oon HH. Prevalence of metabolic syndrome in patients with psoriasis: a cross-sectional study in Singapore. Singapore Med J. 2020 Apr;61(4):194-199. doi: 10.11622/smedj.2019152.
Caroppo F, Galderisi A, Ventura L, Belloni Fortina A. Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis. Eur J Pediatr. 2021;180(6):1739-1745. doi: 10.1007/s00431-020-03924-w.
Bulur I, Erdogan HK, Kocatürk E, et al. The role of irisin in the relationship between psoriasis and insulin resistance. G Ital Dermatol Venereol. 2018;153(4):477-482. doi: 10.23736/S0392-0488.16.05413-4.
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018 Jan-Feb;36(1):21-28. doi: 10.1016/j.clindermatol.2017.09.005.
Choudhary S, Pradhan D, Pandey A, et al. The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. Endocr Metab Immune Disord Drug Targets. 2020;20(5):703-717. doi: 10.2174/1871530319666191008170409.
Jensen P, Skov L. Psoriasis and Obesity. Dermatology. 2016;232(6):633-639. doi: 10.1159/000455840.
Kunz M, Simon JC, Saalbach A. Psoriasis: Obesity and Fatty Acids. Front Immunol. 2019 Jul 31;10:1807. doi: 10.3389/fimmu.2019.01807.
Correia B, Torres T. Obesity: a key component of psoriasis. Acta Biomed. 2015 Sep 14;86(2):121-9.
Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations. Curr Obes Rep. 2020 Sep;9(3):165-178. doi: 10.1007/s13679-020-00380-3.
Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018 Oct 1;98(4):2133-2223. doi: 10.1152/physrev.00063.2017.
Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. Circ Res. 2020 May 22;126(11):1549-1564. doi: 10.1161/CIRCRESAHA.119.315896.
Shimobayashi M, Albert V, Woelnerhanssen B, et al. Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 2018 Apr 2;128(4):1538-1550. doi: 10.1172/JCI96139.
Li B, Xi P, Wang Z, Han X, Xu Y, Zhang Y, Miao J. PI3K/Akt/mTOR signaling pathway participates in Streptococcus uberis-induced inflammation in mammary epithelial cells in concert with the classical TLRs/NF-ĸB pathway. Vet Microbiol. 2018 Dec;227:103-111. doi: 10.1016/j.vetmic.2018.10.031.
Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:3-11. doi: 10.1111/j.1468-3083.2011.04410.x.
Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475. doi: 10.3390/ijms20061475.
Deng Y, Chang C, Lu Q. The Inflammatory Response in Psoriasis: a Comprehensive Review. Clin Rev Allergy Immunol. 2016 Jun;50(3):377-89. doi: 10.1007/s12016-016-8535-x.
Stanescu AMA, Simionescu AA, Florea M, Diaconu CC. Is Metformin a Possible Beneficial Treatment for Psoriasis? A Scoping Review. J Pers Med. 2021 Mar 30;11(4):251. doi: 10.3390/jpm11040251.
Singh S, Bhansali A. Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort). Indian J Endocrinol Metab. 2017 Jul-Aug;21(4):581-587. doi: 10.4103/ijem.IJEM_46_17.
Chang G, Wang J, Song J, Zhang Z, Zhang L. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2020 Nov;31(7):680-686. doi: 10.1080/09546634.2019.1610552.
Hafez VG, Bosseila M, Abdel Halim MR, Shaker OG, Kamal M, Kareem HS. Clinical effects of "pioglitazone", an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. J Dermatolog Treat. 2015 Jun;26(3):208-14. doi: 10.3109/09546634.2014.932324.
Griffiths CEM, van der Walt JM, Ashcroft DM, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol. 2017 Jul;177(1):e4-e7. doi: 10.1111/bjd.15610.
Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013 Apr;68(4):654-662. doi: 10.1016/j.jaad.2012.08.015.
Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol. 2019 Jan;180(1):94-99. doi: 10.1111/bjd.16885.
Polic MV, Miskulin M, Smolic M, Kralik K, Miskulin I, Berkovic MC, Curcic IB. Psoriasis Severity-A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome. Int J Environ Res Public Health. 2018 Jul 13;15(7):1486. doi: 10.3390/ijerph15071486.
Souza CS, de Castro CCS, Carneiro FRO, et al. Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence. J Dermatol. 2019 Jan;46(1):3-10. doi: 10.1111/1346-8138.14706.
Novelli L, Lubrano E, Venerito V, et al. Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. Front Med (Lausanne). 2021 Sep 23;8:737079. doi: 10.3389/fmed.2021.737079.
Owczarczyk-Saczonek A, Purzycka-Bohdan D, Nedoszytko B, et al. Pathogenesis of psoriasis in the "omic" era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis. Postepy Dermatol Alergol. 2020 Aug;37(4):452-467. doi: 10.5114/ada.2020.98284.
Johnson JA, Ma C, Kanada KN, Armstrong AW. Diet and nutrition in psoriasis: analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):327-32. doi: 10.1111/jdv.12105.
Wu AG, Weinberg JM. The impact of diet on psoriasis. Cutis. 2019 Aug;104(2S):7-10.
Chang JY, Park JH, Park SE, Shon J, Park YJ. The Fat Mass- and Obesity-Associated (FTO) Gene to Obesity: Lessons from Mouse Models. Obesity (Silver Spring). 2018 Nov;26(11):1674-1686. doi: 10.1002/oby.22301.
Mizuno TM. Fat Mass and Obesity Associated (FTO) Gene and Hepatic Glucose and Lipid Metabolism. Nutrients. 2018 Nov 1;10(11):1600. doi: 10.3390/nu10111600.
Castellini G, Franzago M, Bagnoli S, et al. Fat mass and obesity-associated gene (FTO) is associated to eating disorders susceptibility and moderates the expression of psychopathological traits. PLoS One. 2017 Mar 10;12(3):e0173560. doi: 10.1371/journal.pone.0173560.
Ford AR, Siegel M, Bagel J, et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. JAMA Dermatol. 2018 Aug 1;154(8):934-950. doi: 10.1001/jamadermatol.2018.1412.